Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKDC | P78527 | 4/20 | 1.00 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.66 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.66 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.66 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.66 |
| ▸ | MAPT | P10636 | 8/20 | 0.60 |
| ▸ | PKM | P14618 | 2/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | KMO | O15229 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29776854 | 1.00 | PRKDC (1.00) | PRKDCPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL15801109 | 0.88 | PRKDC (0.78) | PRKDCPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL5058525 | 0.86 | PRKDC (0.75) | PRKDCPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL4992024 | 0.84 | PRKDC (0.73) | PRKDCPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL14339148 | 0.84 | PRKDC (0.73) | PRKDCPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL27212227 | 0.84 | PRKDC (0.72) | PRKDCPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL5058382 | 0.84 | PRKDC (0.72) | PRKDCPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL5054826 | 0.84 | PRKDC (0.72) | PRKDCPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL5063514 | 0.84 | PRKDC (0.72) | PRKDCPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL7090207 | 0.83 | PRKDC (0.71) | PRKDCPIK3CDPIK3CAPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11833225-B2 | Methods and compositions for efficient gene deletion | CRISPR THERAPEUTICS AG (CH) | 2023-12-05 | — | — | US | claimed |
| EP-3802826-A1 | METHODS AND COMPOSITIONS FOR EFFICIENT GENE DELETION | CRISPR Therapeutics AG (CH) | 2021-04-14 | — | — | EP | claimed |
| US-9511086-B2 | Method for improving immune system function by administering agents that inhibit DNA-dependent protein kinase-directed apoptosis | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2016-12-06 | — | — | US | claimed |
| US-20150366890-A1 | COMPOSITIONS AND METHODS FOR TREATING FUNGAL INFECTIONS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-12-24 | — | — | US | claimed |
| WO-2014130922-A1 | COMPOSITIONS AND METHODS FOR TREATING FUNGAL INFECTIONS | TRUSTEES OF BOSTON UNIVERSITY (US) | 2014-08-28 | — | — | WO | claimed |
| US-20090035394-A1 | USE OF DNA-PK INHIBITION TO SENSITISE ATM DEFICIENT CANCERS TO DNA-DAMAGING CANCER THERAPIES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2009-02-05 | — | — | US | claimed |
| EP-1351946-A2 | MATERIALS AND METHODS TO POTENTIATE CANCER TREATMENT | ICOS CORPORATION (US) | 2003-10-15 | — | — | EP | claimed |
| US-20020165218-A1 | Materials and methods to potentiate cancer treatment | LUITPOLD PHARMACEUTICALS, INC. | 2002-11-07 | — | — | US | claimed |
| WO-2002020500-A2 | MATERIALS AND METHODS TO POTENTIATE CANCER TREATMENT | ICOS CORPORATION (US) | 2002-03-14 | — | — | WO | claimed |
| US-12497614-B2 | Compositions and methods for editing beta-globin for treatment of hemaglobinopathies | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-12-16 | — | — | US | disclosed |
| US-11833225-B2 | Methods and compositions for efficient gene deletion | CRISPR THERAPEUTICS AG (CH) | 2023-12-05 | — | — | US | disclosed |
| EP-4263829-A1 | COMPOSITIONS AND METHODS FOR EDITING BETA-GLOBIN FOR TREATMENT OF HEMAGLOBINOPATHIES | Vertex Pharmaceuticals Incorporated (US) | 2023-10-25 | — | — | EP | disclosed |
| US-20230323404-A1 | COMPOSITIONS AND METHODS FOR INCREASING HOMOLOGY-DIRECTED REPAIR | UNIV CALIFORNIA (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230022146-A1 | COMPOSITIONS AND METHODS FOR EDITING BETA-GLOBIN FOR TREATMENT OF HEMAGLOBINOPATHIES | VERTEX PHARMACEUTICALS INCORPORATED | 2023-01-26 | — | — | US | disclosed |
| CN-1733305-A | Anticancer implantation agent | KONG QINGZHONG (CN) | 2006-02-15 | — | — | CN | disclosed |
| CN-1634586-A | Anti-cancer medicine composition | SHANDONG LANJIN BIOENGINEERING (CN) | 2005-07-06 | — | — | CN | disclosed |
| CN-1628849-A | Anticancer medicine composition | KONG QINGZHONG (CN) | 2005-06-22 | — | — | CN | disclosed |
| EP-1351946-A2 | MATERIALS AND METHODS TO POTENTIATE CANCER TREATMENT | ICOS CORPORATION (US) | 2003-10-15 | — | — | EP | disclosed |
| US-20020165218-A1 | Materials and methods to potentiate cancer treatment | LUITPOLD PHARMACEUTICALS, INC. | 2002-11-07 | — | — | US | disclosed |
| WO-2002020500-A2 | MATERIALS AND METHODS TO POTENTIATE CANCER TREATMENT | ICOS CORPORATION (US) | 2002-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230022146-A1 | COMPOSITIONS AND METHODS FOR EDITING BETA-GLOBIN FOR TREATMENT OF HEMAGLOBINOPATHIES | HBB, HBG1, HBG2 | PRKDC 417/4885PIK3CD 3457/4885PIK3CA 3697/4885 |
| US-20090035394-A1 | USE OF DNA-PK INHIBITION TO SENSITISE ATM DEFICIENT CANCERS TO DNA-DAMAGING CANCER THERAPIES | ATM, CHEK2, DCK | PRKDC 37/4885PIK3CD 816/4885PIK3CA 554/4885 |
| US-20020165218-A1 | Materials and methods to potentiate cancer treatment | DCK, CHEK2, CHEK1 | PRKDC 17/4885PIK3CD 829/4885PIK3CA 454/4885 |
| US-20150366890-A1 | COMPOSITIONS AND METHODS FOR TREATING FUNGAL INFECTIONS | ERG28, DPM1, COXFA4L2 | PRKDC 34/4885PIK3CD 1972/4885PIK3CA 1898/4885 |
| US-12497614-B2 | Compositions and methods for editing beta-globin for treatment of hemaglobinopathies | HBB, HBG1, HBG2 | PRKDC 417/4885PIK3CD 3390/4885PIK3CA 3547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.